Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

jiangsu flag chemical industry co ltd - diflufenican - suspension concentrate - diflufenican anilide/aniline-nicotinanilide active 500.0 g/l - herbicide - field pea | lentil | lupin | pasture (containing clover) | poppy oilseed | drug poppy | oilseed poppy | opium poppy | pulse - amsinckia - suppression | capeweed - suppression | charlock | chickweed - suppression | corn gromwell - suppression | crassula - suppression | deadnettle | hedge or wild mustard | hyssop loosestrife - suppression | indian hedge mustard | marshmallow - suppression | mouse-ear chickweed - suppression | night-scented stock - suppression | paterson's curse | paterson's curse - suppression | pheasant's-eye or adonis | prickly lettuce | rough poppy - suppression | shepherd's purse - suppression | skeleton weed - suppression | sorrel - suppression | stinging nettle - suppression | toad rush - suppression | turnip weed | wild radish or radish weed | wild turnip | wireweed, hogweed - suppression | adonis annua | adonis dentatus | brassica campestris | brassica kaber | brassica rapa ssp. sylvestris | brassica rapa var. sylvestris | brassica sinapistrum | buglossoides arvense | crambling mustard | echium lycopsis | echium spp. | giant mustard | hedge mustard | henbit deadnettle | iron weed | jointed charlock | knotweed

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

shandong rainbow international co ltd - mcpa present as the 2-ethyl hexyl ester - emulsifiable concentrate - mcpa present as the 2-ethyl hexyl ester phenoxy acids-mcpa-ester active 570.0 g/l - herbicide - barley | cereal rye | cereal rye - up to early flag leaf only | grass pasture | grass seed crop | oats | triticale | wheat | whe - bathurst burr | capeweed | charlock | dandelion - taraxacum officinale | fat hen | fumitory | hedge or wild mustard | lincoln weed, sand rocket or mustard | london rocket | noogoora burr | paterson's curse | saffron thistle | scotch thistle | skeleton weed | slender or shore thistle - suppression | spear or black thistle | stinkwort | turnip weed | variegated thistle | volunteer canola | volunteer safflower | volunteer sunflower | wild radish or radish weed | wild sage | wild turnip | blessed thistle | brassica campestris | brassica kaber | brassica rapa ssp. sylvestris | brassica rapa var. sylvestris | brassica sinapistrum | bull thistle | cabbage thistle | carduus marianus | cockleburr | common dandelion | cotton thistle | crambling mustard | echium lycopsis | echium spp. | english dandelion | european dandelion | false star thistle | giant mustard | hedge mustard | heraldic thistle | holy thistle | jointed charlock | lady's thistle | milk thistle | pink weed | purple bugloss | purple viper's bugloss | radi

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

shandong rainbow international co ltd - propyzamide - water dispersible granule - propyzamide benzene active 500.0 g/kg - herbicide - buffalo grass lawn or turf | clover for hay production | clover grown for forage | clover seed crop | common couch lawn or turf - annual or wimmera ryegrass | barley grass | barnyard or water grass | bent grass - agrostis spp. | blackberry nightshade | canary grass | chickweed | english couch or rope twitch | great, ripgut or kingston brome | nettle | paterson's curse | perennial ryegrass | pigweed spp. | prairie or annual prairie grass | prince of wales feather | ryegrass | shepherd's purse | silver grass or rat's-tail fescue | silvergrass - aristida contorta | sorrel - seedling | squirrel-tail fescue or silver grass | summer grass | wild oat | winter grass | wireweed or knotweed - seedling | wireweed, knotweed or hogweed | yorkshire fog grass | agropyron repens | agrostis capillaris | amaranthus cruentus | amaranthus powellii | amaranthus viridis | annual blue grass | annual phalaris | annual pigweed | annual poa | barnyard grass | black nightshade | brome fescue | brome grass | bromus catharticus | bromus stamineus | bromus wildenowii | bunched kerosene grass | common chickweed | echium lycopsis | echium spp. | fallopia aviculare | f

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

shandong rainbow international co ltd - mcpa present as the 2-ethyl hexyl ester - emulsifiable concentrate - mcpa present as the 2-ethyl hexyl ester phenoxy acids-mcpa-ester active 500.0 g/l - herbicide - barley | barley - see label | cereal rye | cereal rye - see label | oats | oats - see label | triticale | triticale - see label - bathurst burr | capeweed | charlock | cotton thistle | dandelion - taraxacum officinale | fat hen | fumitory | lincoln weed - seedling | london rocket | mustard | noogoora burr | paterson's curse | saffron thistle | sheep, shore or winged slender thistle | skeleton weed | spear or black thistle | stinkwort | turnip weed | variegated thistle | volunteer canola | volunteer safflower | volunteer sunflower | wild radish or radish weed | wild sage | wild turnip - brassica spp. | blessed thistle | brassica kaber | brassica sinapistrum | bull thistle | cabbage thistle | carduus marianus | cockleburr | common dandelion | echium lycopsis | echium spp. | english dandelion | european dandelion | false star thistle | giant mustard | holy thistle | jointed charlock | lady's thistle | milk thistle | pink weed | purple bugloss | purple viper's bugloss | radish (wild) | raphanus rugosum | rapistrum weed | sage (wild) | salvation jane | sand mustard | sheep thistle | shore thistle | short-fruited turnip | short-fruited wild t

United States - English - NLM (National Library of Medicine)

tianjin tianyao pharmaceuticals co., ltd. - methylprednisolone (unii: x4w7zr7023) (methylprednisolone - unii:x4w7zr7023) - methylprednisolone tablets are indicated in the following conditions: 1. endocrine disorders primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcemia associated with cancer 2. rheumatic disorders as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) ankylosing spondylitis acute and subacute bursitis synovitis of osteoarthritis acute nonspecific tenosynovitis post-traumatic osteoarthritis psoriatic arthritis epicondylitis acute gouty arthritis 3. collagen diseases during an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus systemic dermatomyositis (polymyositis) acute rheumatic carditis 4. dermatologic diseases bullous dermatitis herpetiformis severe erythema multiforme (stevens-johnson syndrome) severe seborrheic dermatitis exfoliative dermatitis mycosis fungoides pemphigus severe psoriasis 5. allergic states control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: seasonal or perennial allergic rhinitis drug hypersensitivity reactions serum sickness contact dermatitis bronchial asthma atopic dermatitis 6 . ophthalmic diseases severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: allergic corneal marginal ulcers herpes zoster ophthalmicus anterior segment inflammation diffuse posterior uveitis and choroiditis sympathetic ophthalmia keratitis optic neuritis allergic conjunctivitis chorioretinitis iritis and iridocyclitis 7 . respiratory diseases symptomatic sarcoidosis berylliosis loeffler's syndrome not manageable by other means fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis 8. hematologic disorders idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired (autoimmune) hemolytic anemia erythroblastopenia (rbc anemia) congenital (erythroid) hypoplastic anemia 9. neoplastic diseases for palliative management of: leukemias and lymphomas in adults acute leukemia of childhood 10. edematous states to induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. gastrointestinal diseases to tide the patient over a critical period of the disease in: ulcerative colitis regional enteritis 12. nervous system acute exacerbations of multiple sclerosis 13. miscellaneous tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. trichinosis with neurologic or myocardial involvement. systemic fungal infections and known hypersensitivity to components.

Israel - English - Ministry of Health

david margalit & co.ltd - fluconazole - solution for infusion - fluconazole 200 mg / 100 ml - fluconazole - fluconazole is indicated in the following fungal infections.fluconazole is indicated in adults for the treatment of:• cryptococcal meningitis.• coccidioidomycosis. invasive candidiasis.• mucosal candidiasis (including oropharyngeal candidiasis, oesophageal candidiasis, candiduria and chronic mucocutaneous candidiasis).• chronic oral atrophic candidiasis (denture sore mouth) if dental hygiene topical treatment are insufficient.fluconazole is indicated in adults for the prophylaxis of:• relapse of cryptococcal meningitis in patients with high risk of recurrence.• relapse of oropharyngeal or oesophageal candidiasis in patients infected with hiv who are at high risk of experiencing relapse.• prophylaxis of candidal infections in patients with prolonged neutropenia (such as patients with haematological malignancies receiving chemotherapy or patients receiving haematopoetic stem cell transplantation).fluconazole is indicated in term newborn infants, infants, toddlers, children and adolescents aged from 0 to 17 years old:fluconazole is used for the treatment of mucosal candidiasis (oropharyngeal, oesophageal), invasive candidiasis, cryptococcal meningitis and the prophylaxis of candidal infections in immunocompromised patients. fluconazole can be used as maintenance therapy to prevent relapse of cryptococcal meningitis in children with high risk of reoccurrence.therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly.consideration should be given to official guidance on the appropriate use of antifungals.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

elanco australasia pty ltd - enilconazole - topical solution/suspension - enilconazole triazole active 100.0 mg/ml - dermatological preps. - dog | horse | bitch | castrate | colt | donkey | endurance horse | filly | foal | gelding | high performance horses | horses at - dermatomycosis | ringworm - microsporum spp. | ringworm - trichophyton spp. | fungal infections of the skin

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - posaconazole, quantity: 40 mg/ml - oral liquid, suspension - excipient ingredients: sodium benzoate; sodium citrate dihydrate; citric acid monohydrate; titanium dioxide; glycerol; xanthan gum; liquid glucose; peg-40 hydrogenated castor oil; purified water; peg-40 stearate; benzoic acid; glyceryl monostearate; methylcellulose; polysorbate 65; simethicone; sorbic acid; sulfuric acid; flavour - posaconazole is indicated for use in the treatment of the following invasive fungal infections in patients 13 years of age or older: ? invasive aspergillosis in patients intolerant of, or with disease that is refractory to, alternative therapy. ? fusariosis, zygomycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma in patients intolerant of, or with disease that is refractory to, alternative therapy.,posaconazole is also indicated for the: ? treatment of oropharyngeal candidiasis in immunocompromised adults, including patients with disease that is refractory to itraconazole and fluconazole. ? prophylaxis of invasive fungal infections among patients 13 years of age and older, who are at high risk of developing these infections, such as patients with prolonged neutropenia or haematopoietic stem cell transplant (hsct) recipients.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - posaconazole, quantity: 100 mg - tablet, modified release - excipient ingredients: hypromellose acetate succinate; microcrystalline cellulose; hyprolose; croscarmellose sodium; silicon dioxide; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - posaconazole sandoz (posaconazole) is indicated for use in the treatment of the following invasive fungal infections in patients 13 years of age or older:,? invasive aspergillosis in patients intolerant of, or with disease that is refractory to, alternative therapy. ? fusariosis, zygomycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma in patients intolerant of, or with disease that is refractory to, alternative therapy.,posaconazole sandoz is also indicated for the prophylaxis of invasive fungal infections among patients 13 years of age and older, who are at high risk of developing these infections, such as patients with prolonged neutropenia or haematopoietic stem cell transplant (hsct) recipients.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - posaconazole, quantity: 100 mg - tablet, modified release - excipient ingredients: colloidal anhydrous silica; triethyl citrate; microcrystalline cellulose; croscarmellose sodium; propyl gallate; methacrylic acid - ethyl acrylate copolymer (1:1); xylitol; sodium stearylfumarate; hyprolose; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - posaconazole juno is indicated for use in the treatment of the following invasive fungal infections in patients 13 years of age or older:,? invasive aspergillosis in patients intolerant of, or with disease that is refractory to, alternative therapy.,? fusariosis, zygomycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma in patients intolerant of, or with disease that is refractory to, alternative therapy.,posaconazole juno is also indicated for the prophylaxis of invasive fungal infections among patients 13 years of age and older, who are at high risk of developing these infections, such as patients with prolonged neutropenia or haematopoietic stem cell transplant (hsct) recipients.